EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Rhythm Biosciences Limited (RHY) fair value: what the stock is really worth

As of Oct 14, 2026: fair value of Rhythm Biosciences Limited A$0.02, price A$0.07, upside -65.0%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU000000RHY2

RB Thin data Oct 14, 2026

Rhythm Biosciences Limited

RHY · AU

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 65% below what the stock costs today.

Fair value A$0.0238 · Strongly overvalued (−65.0%)
Quality 27/100
Weak Growth (revenue 5y −40.1 %/yr in AUD)
Negative free cash flow
Trails peers (0/7)
Narrow moat 0/100
Thin data
⚠ Dilution
Watch Rhythm Biosciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$2.00 A$0.0470 Fair Value A$0.0238 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.

How to read this chart

60‑month range A$0.0470 – A$2.00 · the A$0.0680 price screens above the A$0.0238 fair value. Dashed = 300-day average. As of Oct 14, 2026.

Follow Rhythm Biosciences in your weekly email

Every Wednesday you see whether Rhythm Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development.

Show more

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

Stock analysis

Rhythm Biosciences Limited (RHY) currently trades at A$0.0680, while our model-based Fair Value estimate is A$0.0238, 65.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Rhythm Biosciences Limited reported revenue of A$85.3K in FY2026 versus A$2.4M in FY2022, a compound −56.7%/yr. Reported net income was −A$5.9M in FY2026.

Key figures

Market cap A$23.5M (≈ $16.4M) · P/S ratio 14.2 · EPS (TTM) A$−0.0200 · Return on equity −276% · Return on assets (EBIT) −195% · Operating margin −3,067% · Revenue growth (YoY) −25.9% · Free cash flow −A$5.3M.

What moves the price

The share trades about 73% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −65%, RHY screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) A$0.0100 A$0.0100 A$0.0100 53
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0100 A$0.0100 A$0.0100 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

Of which business quality 27 · Market factors (momentum, volatility) 21

Profitability 0
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−97.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−69.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−40.1%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−584.1% (2021) → −8,739.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

RHY screens overvalued: fair value 65% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Rhythm Biosciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 127 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −60.0% · Below median
Profitability
Return on assets −96.2% · Bottom 25%
Growth and dividend
Revenue growth −25.9% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 4.62× · Priciest 25%
P/S (TTM) 9.66× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥157.85 ¥173.64 +10% vs RHY
IQVIA Holdings IQV $259.88 $285.87 +10% vs RHY
Illumina, Inc ILMN $278.17 $295.60 +6% vs RHY
Thermo Fisher Scientific Inc TMO $676.76 $686.04 +1% vs RHY
IDEXX Laboratories, Inc IDXX $523.94 $495.84 −5% vs RHY
Danaher Corporation DHR $221.21 $209.18 −5% vs RHY
Mettler-Toledo International Inc MTD $1,550 $644.24 −58% vs RHY
Agilent Technologies, Inc A $171.33 $64.17 −63% vs RHY
Lonza Group LONN CHF 563.40 CHF 151.89 −73% vs RHY
Waters Corporation WAT $433.77 $106.46 −75% vs RHY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rhythm Biosciences Limited · Fair Value
A$0.0238 −65%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Rhythm Biosciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/RHY

Frequently asked questions

Is Rhythm Biosciences Limited (RHY) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of A$0.0238 versus a price of A$0.0680, about −65% upside (overvalued).
What is the fair value of RHY?
Our model-based fair value for Rhythm Biosciences Limited is A$0.0238 (as of Oct 14, 2026), built from audited fundamentals. The current price: A$0.0680.
What is the quality score of RHY?
Rhythm Biosciences Limited has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rhythm Biosciences Limited (RHY)?
Our model-based price target is the fair value of A$0.0238 (as of Oct 14, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Rhythm Biosciences Limited stock forecast for 2026?
Our models put fair value at A$0.0238, about −65% upside versus a price of A$0.0680 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Rhythm Biosciences Limited (RHY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rhythm Biosciences Limited it is A$0.0238 per share (as of Oct 14, 2026), against a price of A$0.0680. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Rhythm Biosciences Limited stock overvalued or undervalued in 2026?
As of Oct 14, 2026, RHY trades above its calculated fair value: price A$0.0680, fair value A$0.0238, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RHY?
No. The price is what the market pays today (A$0.0680); the fair value is what the company's own numbers justify (A$0.0238). For Rhythm Biosciences Limited the two are A$0.0442 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rhythm Biosciences Limited worth?
The market values Rhythm Biosciences Limited at about A$23.5M (market capitalisation, as of Oct 14, 2026). Per share that is A$0.0680; our models calculate a fair value of A$0.0238 per share.
How solid is the balance sheet of Rhythm Biosciences Limited (RHY)?
Balance-sheet figures for Rhythm Biosciences Limited (as of Oct 14, 2026): return on equity −276.0%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is RHY from its 52-week high?
Rhythm Biosciences Limited trades at A$0.0680, about 73% below its 52-week high of A$0.2550 and at the low of A$0.0680 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0238 is for.
Which stocks are comparable to Rhythm Biosciences Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rhythm Biosciences Limited stock attractive at the current price?
The data as of Oct 14, 2026: price A$0.0680, calculated fair value A$0.0238 (−65%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RHY calculated?
We run Rhythm Biosciences Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0238, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Rhythm Biosciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rhythm Biosciences Limited (RHY)?
The closing price on Oct 14, 2026 was A$0.0680. Our model-based fair value is A$0.0238, about −65% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rhythm Biosciences Limited right now?
Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Rhythm Biosciences Limited

How large is the market capitalisation of Rhythm Biosciences Limited (RHY)?
The market capitalisation of Rhythm Biosciences Limited is A$23.5M (≈ $16.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rhythm Biosciences Limited (RHY)?
The price-to-sales ratio of Rhythm Biosciences Limited is 14.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rhythm Biosciences Limited (RHY)?
Earnings per share at Rhythm Biosciences Limited are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rhythm Biosciences Limited (RHY)?
The return on equity (ROE) of Rhythm Biosciences Limited is −276% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rhythm Biosciences Limited (RHY)?
On an EBIT basis the return on assets of Rhythm Biosciences Limited is −195% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rhythm Biosciences Limited (RHY)?
The operating margin of Rhythm Biosciences Limited is −3,067% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rhythm Biosciences Limited (RHY)?
Revenue at Rhythm Biosciences Limited is growing −25.9% versus a year earlier (3y avg −69.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rhythm Biosciences Limited (RHY) generate?
The free cash flow of Rhythm Biosciences Limited is −A$5.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rhythm Biosciences Limited (RHY) hold?
Rhythm Biosciences Limited holds more cash than debt, A$3.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Rhythm Biosciences Limited in the live analysis

One click puts Rhythm Biosciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.